The genetic association of fto variants with metabolic traits in patients with schizophrenia may be modified by antipsychotics
Journal
Journal of Clinical Psychopharmacology
Journal Volume
34
Journal Issue
1
Pages
162-165
Date Issued
2014
Author(s)
SDGs
Other Subjects
clozapine; fto protein; neuroleptic agent; olanzapine; oxygenase; unclassified drug; blood chemistry; blood pressure; body mass; drug efficacy; drug safety; drug tolerability; fat mass; follow up; gene expression; genetic association; genetic susceptibility; genetic variability; genotype; human; laboratory test; letter; mental patient; metabolic disorder; metabolic parameters; metabolic syndrome X; obesity; priority journal; risk assessment; risk factor; schizophrenia; waist circumference; Adult; Aged; Antipsychotic Agents; Biological Markers; Blood Glucose; Female; Genetic Predisposition to Disease; Genetic Variation; Humans; Insulin; Lipids; Male; Middle Aged; Obesity; Phenotype; Proteins; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain; Young Adult
Type
letter